NASDAQ:CRME', 'Cardiome Pharma Corp.', '');

What’s Cardiome Pharma Corporation Ord (NASDAQ:CRME) Upside After This Short Interest Decrease?

December 10, 2017 - By Maria Brooks

 What's Cardiome Pharma Corporation Ord (NASDAQ:CRME) Upside After This Short Interest Decrease?

Investors sentiment increased to 0.83 in 2017 Q2. Its up 0.06, from 0.77 in 2017Q1. It improved, as 5 investors sold Cardiome Pharma Corp. shares while 7 reduced holdings. 1 funds opened positions while 9 raised stakes. 15.20 million shares or 8.53% more from 14.00 million shares in 2017Q1 were reported.
Jpmorgan Chase And, New York-based fund reported 155,095 shares. Pnc Financial Services Grp Incorporated owns 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME) for 51,400 shares. Putnam Ltd Limited Liability Company reported 0.05% in Cardiome Pharma Corp. (NASDAQ:CRME). Deutsche Bank & Trust Ag stated it has 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Alphaone Investment Ser Ltd Liability has invested 0.77% in Cardiome Pharma Corp. (NASDAQ:CRME). Morgan Stanley has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Wells Fargo & Mn reported 960 shares. Rock Springs Cap Mgmt Ltd Partnership invested 0.27% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). 2.88M were reported by Clough Limited Partnership. Royal Natl Bank Of Canada invested in 0% or 1,051 shares. 45 are owned by Bank Of America Corporation De. Gru One Trading Limited Partnership holds 0% or 7,441 shares. Renaissance Limited Liability Company holds 0% or 350,713 shares. Westfield Company Ltd Partnership reported 5.29M shares. Knott David M has invested 0.25% in Cardiome Pharma Corp. (NASDAQ:CRME).

The stock of Cardiome Pharma Corporation Ord (NASDAQ:CRME) registered a decrease of 20.19% in short interest. CRME’s total short interest was 58,100 shares in December as published by FINRA. Its down 20.19% from 72,800 shares, reported previously. With 232,200 shares average volume, it will take short sellers 0 days to cover their CRME’s short positions. The short interest to Cardiome Pharma Corporation Ord’s float is 0.25%.

The stock increased 11.96% or $0.1699 during the last trading session, reaching $1.5899. About 354,451 shares traded or 172.91% up from the average. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since December 10, 2016 and is downtrending. It has underperformed by 27.72% the S&P500.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $55.63 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Cardiome Pharma Corp has $12.50 highest and $3.50 lowest target. $8.10’s average target is 409.47% above currents $1.5899 stock price. Cardiome Pharma Corp had 14 analyst reports since August 11, 2015 according to SRatingsIntel. H.C. Wainwright initiated it with “Buy” rating and $9.50 target in Wednesday, June 1 report. The stock has “Speculative Buy” rating by Mackie on Friday, May 6. The company was maintained on Friday, March 11 by Brean Capital. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, November 15. The stock has “Buy” rating by LB Securities on Friday, August 14. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) has “Buy” rating given on Tuesday, August 22 by H.C. Wainwright. On Monday, August 21 the stock rating was maintained by Canaccord Genuity with “Buy”. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Hold” rating by Zacks on Wednesday, August 26. The rating was downgraded by Mackie to “Hold” on Wednesday, October 12. Zacks downgraded Cardiome Pharma Corp. (NASDAQ:CRME) on Tuesday, August 11 to “Buy” rating.

More important recent Cardiome Pharma Corp. (NASDAQ:CRME) news were published by: which released: “Cardiome Pharma Corp. to Host Earnings Call” on November 14, 2017, also published article titled: “BRIEF-Cardiome announces commercial launch of BRINAVESS in Canada”, published: “Cardiome Pharma Corp. Announces Voting Results” on June 23, 2017. More interesting news about Cardiome Pharma Corp. (NASDAQ:CRME) was released by: and their article: “Cardiome Pharma: The Pieces Are Coming Together” with publication date: May 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.